GB2252105A - Toxin uses - Google Patents

Toxin uses

Info

Publication number
GB2252105A
GB2252105A GB9125997A GB9125997A GB2252105A GB 2252105 A GB2252105 A GB 2252105A GB 9125997 A GB9125997 A GB 9125997A GB 9125997 A GB9125997 A GB 9125997A GB 2252105 A GB2252105 A GB 2252105A
Authority
GB
United Kingdom
Prior art keywords
toxin
cell
combined
mitogenic
fermentations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9125997A
Other versions
GB9125997D0 (en
Inventor
Neil Chanter
Alistair Lax
Juan Enrique Rozengurt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Animal Health
Original Assignee
Institute for Animal Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Animal Health filed Critical Institute for Animal Health
Publication of GB9125997D0 publication Critical patent/GB9125997D0/en
Publication of GB2252105A publication Critical patent/GB2252105A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The toxin from Pasteurella multocida, which causes atrophic rhinitis in pigs, has been characterised and been shown to be highly mitogenic. It may be used to accelerate cell growth (in fermentations, in bone marrow to be returned to the patient, and in wounds). Mitogenic fragments of it may be combined with cell-targeting entities, and cell-binding portions of it may be combined with cytotoxic or other pharmacologically active agents. The gene for the toxin has been cloned and expressed in E. coli.
GB9125997A 1989-06-29 1991-12-06 Toxin uses Withdrawn GB2252105A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898914984A GB8914984D0 (en) 1989-06-29 1989-06-29 Nucleotide sequences
PCT/GB1990/000992 WO1991000100A2 (en) 1989-06-29 1990-06-27 Toxin uses

Publications (2)

Publication Number Publication Date
GB9125997D0 GB9125997D0 (en) 1992-05-20
GB2252105A true GB2252105A (en) 1992-07-29

Family

ID=10659288

Family Applications (2)

Application Number Title Priority Date Filing Date
GB898914984A Pending GB8914984D0 (en) 1989-06-29 1989-06-29 Nucleotide sequences
GB9125997A Withdrawn GB2252105A (en) 1989-06-29 1991-12-06 Toxin uses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB898914984A Pending GB8914984D0 (en) 1989-06-29 1989-06-29 Nucleotide sequences

Country Status (4)

Country Link
EP (1) EP0482018A1 (en)
JP (1) JPH05500657A (en)
GB (2) GB8914984D0 (en)
WO (1) WO1991000100A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK120792D0 (en) * 1992-09-30 1992-09-30 Bioteknologisk Inst PROTEIN
GB9524807D0 (en) * 1995-12-05 1996-02-07 Smithkline Beecham Plc Novel compounds
DE102004035606A1 (en) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier for drugs for obtaining oral bioavailability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc.Natl.Acad.Sci. USA 1990, 87, 123-127 *

Also Published As

Publication number Publication date
WO1991000100A3 (en) 1991-04-04
WO1991000100A2 (en) 1991-01-10
GB9125997D0 (en) 1992-05-20
GB8914984D0 (en) 1989-08-23
EP0482018A1 (en) 1992-04-29
JPH05500657A (en) 1993-02-12

Similar Documents

Publication Publication Date Title
HU902145D0 (en) Process for producing medical preparatives suitable for systematic treating of preneoplastic lesions with cytoquinine content
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
NZ228130A (en) Therapeutic composition comprising fenofibrate and a solid surfactant which has been co-micronised; preparatory process
HK184896A (en) Pharmaceutical composition comprising loratadine ibuprofen and pseudoephedrine
NZ333380A (en) 6-O-methylerythromycin A crystal form I (clarithromycin) and preparation thereof
SE8504945D0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTHRACYCLINE GLYCOSIDES
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
UA56989C2 (en) PHYSIOLOGICALLY ACTIVE PEG-CONJUGATE OF a-INTERFERON, A METHOD FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR TREATMENT OR PROPHYLAXIS OF IMMUNOMODULAR DISEASES
HK1056683A1 (en) New pharmaceutical composition
EP0873141A4 (en) Compositions and methods for therapeutic use
WO1998007745A3 (en) Compositions and methods for treating infections using analogues of indolicidin
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
TW349021B (en) Pharmaceutical compositions containing interleukin-12 for preventing graft versus host disease
CA2204277A1 (en) Combined meningitis vaccine
AU689817B2 (en) Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof
EP0797999A3 (en) Formulations of obesity protein
CA2234263A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection
FR2644066B1 (en) STABILIZED COMPOSITIONS COMPRISING FGFS, PROCESS FOR OBTAINING THEM AND THERAPEUTIC, SURGICAL AND COSMETOLOGICAL APPLICATIONS
WO1994008613A3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy
SE9603725D0 (en) New teatment
GB9320820D0 (en) Compounds for medicinal use
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
AU6245390A (en) Recombinant aprotinin variants - genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
MX9704034A (en) Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof.
GB2252105A (en) Toxin uses

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)